Home / Transcripts / American Well Corporation (AMWL) · February 12, 2026

American Well Corporation (AMWL) Earnings Call Transcript

February 12, 2026

New York Stock Exchange US Health Care Health Care Technology earnings 43 min

Earnings Call Speaker Segments

Ido Schoenberg executive
#1

Thanks, operator, and good afternoon to all of you. For American Well Corporation, 2025 proved to be a decisive year. Our focus grew sharper, we carried out a significant transformation, and we came into 2026 with a clear line of sight toward our objective of reaching cash flow breakeven from operations during Q4. I'll address three topics today: the market forces shaping what we're doing, what we accomplished in 2025, and what we intend to do in 2026. Mark will follow me with the specifics on our financials and guidance. We'll open things up for your questions once that's done. As we look at health care going into 2026, one thing stands out: a pronounced movement toward operating more efficiently. Payers along with health systems are pushing hard for consolidation onto single platforms, assured returns on investment, and automation built to industrial strength. When you're juggling a vast array of point solutions — one addressing diabetes, another for MSK, a third for mental health, yet another for wellness, and so on — the result is enormous administrative burden; you get security weaknesses, and you get fragmented experiences for members; sponsors end up forced into the role of system integrators, something they frequently aren't properly set up to do. And the pressure keeps building. The Medicare population is growing older at a fast clip. Drug costs are spiking. Health care expenses overall continue to rise, particularly in behavioral health and around GLP-1 use. Shortages of clinicians are getting worse. Subsidies are disappearing. Payer margins are shrinking quickly. Care delivered with technology's help is no longer something nice to have; it's a necessity. What hybrid care can deliver is now evident. Pair automation with intelligent deployment of clinicians' time to lower costs and achieve better results. AI is speeding up this transition. It's reshaping engagement, intake, decision support, workflows for delivering care, risk stratification, and how outcomes get measured. That brings enormous opportunity along with genuine risk that has to be handled. Payers and health systems understand this; their adoption of technology-enabled care isn't a trial — it's their central mechanism for cutting costs, achieving better outcomes, and satisfying patient expectations. And more and more, they want that delivered via one unified platform. A technology-enabled care platform — a tech platform — offers obvious benefits. Sponsors keep their brand at the forefront. They retain complete access to data; they hold the relationship and receive credit for the value created. Engaging patients becomes both more efficient and more effective. Our tech platform supports an API-first ecosystem. It lets sponsors bring their digital stack together onto a single infrastructure. Clinical programs can be introduced, exchanged, or discontinued swiftly. We make vendor rationalization easier — that's the practice of reviewing digital health partnerships and ruthlessly eliminating programs that underperform. Managing vendors becomes less complicated. Vendor sprawl, together with its scattered IT approaches, isolated data, and everyday inefficiencies, gets cut down. Tracking outcomes across the whole person and across cohorts turns into something you can act on. This platformization lowers integration expenses. It brings data lakes together for stronger analytics; it makes risk stratification possible so high-risk members can be identified and helped early. And it transforms the member experience dramatically by offering one simple, personalized, familiar front door for every care need. Given AI, and particularly AI-powered clinical programs expanding so quickly, being able to test and refine is essential. And that means making sure licensed doctors are the ones steering care through intelligent integration; during 2025, we made a firm decision: to concentrate solely on delivering the top technology platform available. Every party involved benefits. Patients get personalized, easy access to an expanding set of AI-driven care offerings. Payers, employers, and government sponsors see lower expenses, better results, and outstanding experiences while remaining nimble enough to boost ROI as offerings change. Member experience turns essential in 2026 once ACA subsidies lapse and cause members to drop off, which hurts payer risk mix. Sponsors also gain strong ROI from American Well Corporation’s demonstrated platform-native clinical offerings — urgent care, behavioral health, and virtual primary care — plus the ability to plug in any third-party solution. It additionally lets payers preserve network adequacy, particularly in behavioral health services, where the gap between supply and demand keeps climbing. Effective collaboration with partners such as Vida, a digital companion aimed at curbing inappropriate GLP-1 use, or SOAR for managing MSK costs, are excellent illustrations. Health systems can bring remote care to their own providers; they can deliver services via our platform outside their catchment area; and they can enhance their care with third-party offerings. All sponsors may treat their tech platform as the infrastructure required to tap federal funding — initiatives such as ACCESS, BALANCE, or the rural health transformation. Lastly, resilience has become a major purchasing criterion. Payers want partners possessing zero-trust architecture and demonstrated resilience. American Well Corporation’s agreement with the Defense Health Agency stands as strong proof. It shows our platform satisfies the toughest security standards anywhere. With tech as our only focus, we are forging deeper, lasting ties with payers, government, and health systems. We finished our shift from a telehealth provider into dependable, trusted enterprise infrastructure. The American Well Corporation platform has turned into a vital utility. It addresses existential needs for our customers by successfully delivering consolidation, automation, and clinical ROI; this ties our success to our clients’ success and opens a route to higher-quality, higher-margin growth; we anticipate that our high-quality growth will be driven by the potent secular trend of tech adoption. As AI transforms health care, we give our customers a steady, safe, and effective framework for adopting it while staying flexible and nimble. After our focused commitment in 2025, we acted swiftly. We shed noncore activities. The sale of APC is one instance; we reorganized our company and sharply cut our cost base; we adjusted our roadmap and go-to-market investments. Clients and prospects reacted. 2025 delivered substantial commercial momentum. Within the payer segment by itself, we completed over 15 payer contract renewals accounting for the vast majority of our current payer subscription revenue. Along with our new logo wins, we confirmed our platform strategy, reinforced our recurring high-quality revenue base, and set ourselves up well for same-store expansion. Illustrations include the DHA renewals last summer, Blue Cross Blue Shield of Florida going live this January, and most significantly, our three-year renewal with Elevance. Coming into 2026, we've made responsible cuts to noncore work of lower quality. The top line for 2026 is reduced in size, yet what remains is mostly sticky revenue of high quality and strong upside; because of that, we can see a clear route to hitting our objective of breakeven cash flow during Q4 of this year. During 2026, we'll invest with tight fiscal discipline in innovations that broaden our competitive edge: patient experience enhanced by AI, quicker integration with third parties, improved use of clinical data, and deployments that are faster and simpler. A strong, fresh leadership group has been brought together — seasoned executives whose track records are proven, drawn from world-class companies, aligned and motivated by our mission, which is clear. Our execution path is focused, and the market plainly values our offering. We begin 2026 with cash reserves that are healthy, zero debt, a recurring revenue base that is strong and dependable, and an obvious route to growth across many years. The road we traveled was neither brief nor simple. To our team members, clients, and partners, my deep gratitude for remaining with us along this road. That trust travels with us as we execute and deliver throughout 2026 and in the years ahead. Now I'll hand the call to Mark for the financial results. Mark?

Mark J. Hirschhorn executive
#2

Thanks for that, Ido, and good afternoon, everyone. To get today's call started, I'll go over several noteworthy items from full year 2025, then I'll examine our fourth-quarter financial performance, and finally I'll share where our initial guidance sits for the first quarter along with the whole 2026 fiscal year. Starting with the full year — for American Well Corporation, 2025 was a major period of refocusing our efforts and achieving financial progress. We ended the year with total revenue of $249.3 million. One important thing to note is that subscription revenue became an even larger and more stable share of our business, accounting for 53% of total revenue versus 45% in 2024; that deliberate shift demonstrates how we've made SaaS-based revenue streams — ones that are higher quality and more predictable — a priority. When it comes to profitability, we made considerable progress. Over the full year, we cut net loss and adjusted EBITDA losses each by roughly $100 million, driven by disciplined cost actions and a leaner, more focused operating model. As for the fourth quarter, we delivered solid results on both revenue and adjusted EBITDA, reflecting improved subscription retention, greater visit volume in specialty care and virtual primary care, and meaningful cost efficiencies from successfully executing our transformation plan; on top of that, early benefits from AI integration across our operations began to show up. Cash burn for the quarter came to approximately $19 million, with revenue in the range of $195 million to $205 million and an adjusted EBITDA loss in the range of $7 million to $5 million. Altogether, our fourth-quarter achievements confirm that the steps we set in motion at the start of 2025 are producing durable financial gains and stronger operating leverage. Let's start with the top line. We generated $55.3 million in total revenue for the quarter, representing a 22.1% decline from the same period a year ago. Within that, subscription revenue was $28.8 million, down 22% year over year. A number of factors account for that decline: chiefly, the reduction to our DHA contract that took effect last summer, together with customer churn from earlier in 2024, and to a lesser extent, the fact that we reordered priorities in certain parts of the business to focus on our core payer and government markets. Moving to Amwell Medical Group, or AMG, visit revenue reached $23.7 million, which is 18.7% below a year ago — that mirrors the APC divestiture plus some residual churn carried over from 2024. On the volume front, paid AMG visits remained steady, landing at approximately 340,000 for the quarter. During the quarter, we logged 1.0 million total visits across the platform. That's compared with 1.4 million in 2024, a 28.4% decrease year over year, and it's consistent with the portfolio adjustments I referenced earlier. Cost of goods sold was $27.0 million for the quarter, leaving us with $28.3 million in gross profit — a 17.6% decline relative to the same period last year. Gross margin came in at 51.2%, which represents a decline of 280 basis points versus the same period last year. While near-term margin pressure was something we did experience, the mix of our revenue continues shifting toward SaaS offerings that come with better margins, and as we build more scale, we anticipate that transition will assist in driving margin expansion. Let's turn next to operating expenses. Total operating expenses, once depreciation and amortization are excluded, came to $55.3 million. That amounts to a 30.7% reduction compared with the prior year. We recorded a substantial enhancement in operating expenses relative to revenue, which came in at 96.7%, versus 108.7% in Q4 of last year — evidence of what our transformation work and sustained cost discipline have produced. For the quarter, adjusted EBITDA was a loss of $10.3 million. Measured against a loss of $12.7 million in 2025, that marks an improvement, and relative to the $22.8 million figure posted in 2024, it amounts to a 55% gain. Net loss was $25.2 million, versus $30.7 million in the third quarter — a 43.5% year-over-year improvement. Moving to the balance sheet: across the fourth quarter, we burned roughly $19.0 million in cash. We ended the year with approximately $182.0 million in cash and marketable securities, and importantly, we have no debt. Turning to guidance: for the full year 2026, we expect revenue between $195.0 million and $205.0 million. AMG visits should come in somewhere between 1.32 million and 1.37 million, with an adjusted EBITDA loss in the $24.0 million to $18.0 million range, and for Q1 of 2026, revenue is expected to land between $48.0 million and $53.0 million, with an adjusted EBITDA loss of $7.0 million to $5.0 million. Based on where we are today and how we continue to execute, we expect the company to achieve positive cash flow from operations in the fourth quarter of this year. This guidance reflects our assumptions around stable subscription retention, visit volume trends in both specialty care and virtual primary care, our continued cost control work, and the growing advantages we see from automation and AI-driven efficiencies throughout the organization. To wrap up, 2025 proved to be a year in which we honed our focus and achieved genuine progress. We directed our efforts toward our two primary customer segments — payers and government entities — while readying the business to return to dependable, sustainable growth. Simultaneously, we made significant progress cutting cash burn and losses by about $100 million, which places us firmly on track to deliver positive cash flow from operations by Q4 of this year. Not one of these results would have been possible without the dedication and hard work of our entire team, and I want to express my sincere gratitude to them. We look forward to keeping you updated on our progress this year; with that, I'll turn it back to Ido for his closing remarks.

Ido Schoenberg executive
#3

Thanks, Mark. We feel good about what we accomplished during 2025. We sharpened our attention on the tech platform, confirmed that demand in the market is strong, and made meaningful gains in both efficiency and our cost structure; as we head into 2026, we have clear visibility into ongoing performance improvement, which puts us in a solid position to reach our objective of breaking even on cash flow from operations in Q4. Just as important, the adjustments we've implemented have boosted the quality of our revenue. Our clients today get even more value out of working with us, which leads to relationships that last longer and stick harder, producing higher margins more dependably and offering much greater potential for same-store growth. As AI-driven clinical programs expand exponentially, and payers, government, and health systems increasingly need infrastructure to deploy those programs safely and effectively, we believe American Well Corporation has hit an exciting inflection point. We're looking forward to an important year ahead; with that, let's open it up for questions. Operator?

Stanislav Berenshteyn executive
#4

Hello there. Corey speaking, filling in for Stan. Seeing movement toward breaking even on free cash flow is heartening, even with the difficulties we're facing around retention. When we look ahead to 2026, what's the right way to think about the timing for when contracts with current clients come up for renewal? Also, is there anything more you can share regarding the opportunities you have in government? Thank you.

Ido Schoenberg executive
#5

Hello, Corey. In my earlier prepared remarks, I noted that during 2025 we recorded 50 contracts, the majority being renewals. Through those, we substantially locked in our base of recurring revenue. Because of that, the number of renewals still open for 2026 is notably smaller, though there is a single significant exception: the DHA renewal, which we anticipate occurring this summer. We feel quite good about the value we deliver alongside the DHA and about the traction, and we're optimistic that our results and our solid relationship leave us positioned favorably for a multiyear renewal within that key market segment as well.

Jailendra Singh analyst
#6

Yes, thank you, and I appreciate you fielding my questions. Ido, you mentioned that 2026 would be a year focused on operational efficiencies. You devoted a great deal of time to AI. It's clear that AI will play a significant part in this, and you've been among the early adopters. But what's your view on some of the newer AI firms and trends that are finding opportunities when it comes to having an effect in health care? And obviously, they're all attempting to make a substantial push given how much inefficiency exists in the system. How do you expect the competitive landscape to develop with these new players entering the market?

Ido Schoenberg executive
#7

Thank you, Jailendra; we're extremely bullish and optimistic regarding AI's impact on health care, with the clear caveat and exceptions of risk management and similar areas. But on the whole, this trend is quite powerful. AI is capable of many things, and at American Well Corporation, we applied AI extensively throughout our whole workflow and operations and within our own product. That said, AI's greatest ability to affect our customers lies in clinical programs, and those usually concentrate on a single therapeutic area at a time, whether that's MSK, GLP-1, diabetes, blood pressure, and so forth. Combining those AI programs and being able to integrate, switch, and sustain multiple AI programs proved to be a major challenge for our customers. And you have to link them into a consistent, highly regulated infrastructure; so, for instance, when you build an entry point, a digital door for your digital assets, and it functions for your own members, you want to keep it consistent, and you don't want to rebuild it every time you swap one AI program for another. And that is truly our role. Our role is to pair the regulated baseline infrastructure with a tsunami of AI programs reliably; we aren't aware of many, or even any, companies doing precisely that at present; and very importantly, we are already deployed with a new platform with a very large market share footprint right now that is demonstrating it works very effectively, and the opportunity is really to leverage AI and to add AI to this infrastructure rather than replace it. So, to sum up, we believe that AI will be embraced and taken up considerably across our client base, and we believe that our platform would serve as an important utility as our clients do so.

Jailendra Singh analyst
#8

Okay, thank you very much.

David Larsen analyst
#9

Could you discuss a few of the factors working against us and in our favor that might lead to either a higher outlook or put the guidance at risk? Many thanks.

Ido Schoenberg executive
#10

Hello, Mark speaking here. I believe the

Mark J. Hirschhorn executive
#11

Probably the biggest potential boost would come from faster uptake of our tech-driven offering among the options out there; at this moment we're involved in RFIs and RFPs across all 50 states. There's also a sizable opening for us in several additional government sectors. We anticipate learning during Q2 — just a handful of months away — just how extensive our role will be and the timing for when that money starts coming in. None of those dollars have been factored into the 2026 plan we have now, yet we firmly think that because the pipeline today is bigger than at any prior point in American Well Corporation's entire history, a large portion of it will turn into backlog that starts paying off during 2027. On the subject of challenges, naturally we have a DHA renewal coming up this summer. Our confidence is very high that it gets renewed once more, and ideally on a longer-term basis. Apart from that, none of our other significant agreements come up for renewal during 2026.

David Larsen analyst
#12

Could you go over the DHA renewal again — you brought up a step down in DHA revenue. What caused that? Is winning it back possible this summer? If so, on the same annual run-rate basis, how big an incremental revenue step up tied to DHA would that be? Thanks.

Mark J. Hirschhorn executive
#13

Yes, that's right. Sadly, because DoD eliminated our digital behavioral health and automated care programs during summer 2025, we went through that. At first we had introduced it at a chosen set of sites; results were extremely good. Those programs saw very strong uptake, yet an overall mandate for cost efficiency meant they weren't renewed when the contract, including the base contract, came up for renewal. Regarding where that contract stands, we feel very, very confident, and we see a chance to look again at folding those 2 programs into the base platform renewal this coming summer. On materiality: it's significant. It's material. We don't reveal the contract's total value, though I believe we hinted previously, and would continue to do so, that putting those 2 elements back in would definitely be material.

David Larsen analyst
#14

Thanks very much.

Mark J. Hirschhorn executive
#15

You are welcome.

Craig Hettenbach analyst
#16

Yes. Thanks. Ido, I'll pick up on what you said about a somewhat smaller top line but better quality and stickier business. Do you view 2026 as the baseline for being able to get back to growth? And with the business as it stands in 2026, how does long-term growth shape up? What kind of growth profile can this business produce?

Ido Schoenberg executive
#17

Hi, Craig. You're exactly right. In fact, 2 years back, we sold a huge number of products across a huge number of market segments. Market-product fit differed from one to the next. As a reminder, we had APC, and we played psychiatry, at times in person in hospitals; we ran a very large hardware business, inpatient solutions, competing head-on with EHRs, and that sort of thing. While some of that remains, and we will always serve our clients very well, we've essentially now collapsed all those numerous products into a single platform — the technology-enabled care platform — and tied it to our own native services plus an expanding array of third-party services you can layer even more onto. Looking at the markets today, and I noted in my prepared remarks how incredibly important and valuable it is to divert clinical demand away from brick and mortar into technology-enabled care, everyone is convinced. This infrastructure is something you truly need. So we fully anticipate that our sponsors, our clients, will put money into encouraging their members to use it more and more often — through marketing and through cost attractiveness and that sort of thing. So a strong secular trend exists that isn't going anywhere over the next 2 years toward having people use our platform, not just for urgent care, as in the early days, but truly across the whole care continuum. The infrastructure we built is big and deep. It isn't something you change daily. Our sales cycles take, for a reason, 9 to 12, at times more, months. But once implemented, they're genuinely tied into the financial and clinical backbone of the sponsors, both in terms of incoming traffic and in terms of outgoing analytics and reporting. Yet the middle ground, the space where all those AI-driven clinical programs sit, is expanding extremely rapidly. And there's genuine motivation to add more; and as that occurs, we stand to gain from high-margin revenue. I'll give you just 1 example. I don't recall any CFO leadership at any payer customer of ours that isn't incredibly worried about GLP-1 spending. The ability to very easily add Vida or other programs to the existing integrated

Craig Hettenbach analyst
#18

infrastructure is extremely attractive

Ido Schoenberg executive
#19

for our customers to do, and we make it incredibly simple and easy for them to do that. In summary, we think same-store growth offers us a significant revenue opportunity. Beyond that, as you're aware, we put a great deal of investment into breaking into government markets, which are very difficult to penetrate. Our results there make me very happy. And many other big opportunities exist that closely resemble the one we showed with the DHA.

Mark J. Hirschhorn executive
#20

So we do believe that the government sector

Ido Schoenberg executive
#21

This also stands for a tremendous chance to expand, through brand-new customers as well as growth within accounts we already serve — similar to what Mark described not long ago, in order to bring back our behavioral health offerings and potentially additional alternatives. The results we’ve delivered for current clients haven’t gone unnoticed by others. A large number of them feel real pressure to bring on those programs, yet the setup they use for that right now is far smaller in scale. Given cost constraints, many payer IT teams are considerably leaner these days, which means acting as the integrator across all of those programs and then pairing them with a separate ASO has grown increasingly hard. American Well Corporation, along with the American Well Corporation platform, comes across as a strong answer for them and, plainly, for the vendors too, who can speed up their reach and their offerings into those heavily regulated clients by leveraging what we’ve built. Thank you.

Eric Percher analyst
#22

I'd like to explore a bit further what's driving the better revenue quality. Looking at the guidance for the upcoming year, it seems there's some pulling back — I'm aware you'd also weighed some divestitures. Could you tell us more about what you're stepping away from and why revenue is coming in below what we'd anticipated? And is none of that tied to the divestitures you've evaluated? Down the road, would those end up helping the bottom line incrementally even as they shrink the top line from where we sit in 2026?

Ido Schoenberg executive
#23

Absolutely. Eric, essentially what we've done is consolidate everything around a single offering — the American Well Corporation platform. It performs the functions we outlined before, and it performs them exceptionally well. As you're aware, we previously had additional offerings in market segments where product-market fit wasn't strong. We sold off the APC, and we pulled back from other areas that aren't core. Basically, the one product we have today remains an excellent fit for every market segment we served previously, yet it's a single product spanning those segments rather than numerous products spanning numerous segments. For payers and government, the value proposition is both powerful and substantial. A substantial share of our revenue comes from that source. And because it links millions and tens of millions of people who are increasingly motivated to engage with the platform throughout the ecosystem, that's also where our biggest growth opportunity lies. That said, plenty of health systems now carry risk. A lot of them wish to take part in various government programs such as ACCESS. To accomplish that, they genuinely gain from having something like the American Well Corporation platform, since you're able to layer all those highly efficient clinical programs onto what they already provide in a manner that's integrated right out of the box and executed very efficiently; this lets us stay very efficient with one highly appealing, differentiated product, capitalize on secular demand that keeps rising, at considerable expense to expand it. After we're implemented, introducing programs and gaining more traction costs far less than building the platform we've spent the last few years creating; and naturally, few such platforms exist in the market. So we absolutely anticipate that the recent example we shared involving Blue Cross Blue Shield of Florida won't be a lone, uncommon case. Mark, I don't know whether there's anything you'd like to add.

Eric Percher analyst
#24

Let me put that more precisely. When you say 2026 revenue and EBITDA, is that assuming a complete departure from the business that we talked about possibly exiting?

Ido Schoenberg executive
#25

That's my understanding, yes. A bit still remains, though its share keeps shrinking, both in percentage points and in relative terms, and eventually it will be so small as to not matter across the coming two years.

Eric Percher analyst
#26

Thanks.

Ryan MacDonald analyst
#27

Hello, and thank you for fielding my questions. Ido, it's wonderful to hear that those 15 renewals were completed, clearly, along with that big three-year renewal involving Elevance. I'd like to know whether you might explain the way those renewals, or the conversations around them, are shaping your strategy for reaching the market when it comes to net new possibilities? And when you consider 2026, looking across government, payer, and provider, where are you moving most quickly, or where are you truly concentrating those go-to-market efforts when it comes to acquiring net new logos for the company? Thanks.

Ido Schoenberg executive
#28

Certainly, Ryan. I'm happy to report that every one of our renewals, insofar as they concern the payers that we and others serve, centered on the identical offering — the new American Well Corporation platform; and in many respects, even though these are technically renewals, given that the offering differs so greatly from what they previously had and our role differs so greatly, you can view them in many respects as a new sale or nearly a net new sale. You should also keep in mind that whenever customers renew and migrate onto the new platform, that brings with it deep integration into financial and clinical backbones. So it isn't something you accomplish particularly fast. You approach it as a long-term investment. The worth of current customers is now shown quite convincingly, and when we bring on new customers, the workflow is really very comparable; so replicating it becomes far simpler and easier and far more efficient moving forward. As I said before, when we examine multiyear growth, the clearest and most impactful category is same-store growth, gaining from additional programs reaching more individuals who will use it more frequently and more efficiently, and really gaining from those secular tailwinds; beyond that, as Mark said before, we hold the biggest pipeline in our company's history, I believe, that I can recall, at minimum, as of now, and that's the whole story. Nothing else matters. It concerns our single platform and its clinical services and the value it ought to produce as an infrastructure for adopting ever more AI-powered clinical programs. We possess plenty of proof points, plenty of success points at very large scale. When I examine the segments, commercial payers represent our sweet spot — Blues and others. Yet there's no doubt that our edge in government is even greater. And the explanation is that this is a genuinely high barrier-of-entry segment once you consider cybersecurity, regulations, matters of that kind, and we currently have that. A tremendous amount of time, effort, and resources went into reaching that point, and it delivers really, really strong performance; as a result, we absolutely anticipate meaningful growth from this over the coming few years, and finally, our view is that health systems will take part, though in proportion, with their contribution likely ending up below that of the first two segments I just referenced.

Ido Schoenberg executive
#29

Thanks, operator, and thanks to all of you for being here; we truly appreciate the backing you’ve shown for American Well Corporation, and we’re eager to speak with you again before long. Enjoy the rest of your evening. That wraps up the conference for today.

Operator operator
#30

Thank you for your participation. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete American Well Corporation transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to American Well Corporation earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.